The genus Alphavirus contains members that threaten human health, both as natural pathogens and as potential biological weapons. Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) enter cells readily and can inhibit viral replication through sequence-specific steric blockade of viral RNA. Sindbis virus (SINV) has low pathogenicity in humans and is regularly utilized as a model alphavirus. PPMO targeting the 5'-terminal and AUG translation start site regions of the SINV genome blocked the production of infectious SINV in tissue culture. PPMO designed against corresponding regions in Venezuelan equine encephalitis virus (VEEV) were likewise found to be effective in vitro against several strains of VEEV. Mice treated with PPMO before and after VEEV infection were completely protected from lethal outcome while mice receiving only post-infection PPMO treatment were partially protected. Levels of virus in tissue samples correlated with animal survival. Uninfected mice suffered no apparent ill-effects from PPMO treatment. Thus, PPMO appear promising as candidates for therapeutic development against alphaviruses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447162 | PMC |
| http://dx.doi.org/10.1016/j.virol.2008.03.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
is essential for zebrafish embryogenesis and pronephros formation.
Front Cell Dev Biol
December 2024
Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, United States.
Background And Objectives: Friedreich's Ataxia (FRDA) is a genetic disease that affects a variety of different tissues. The disease is caused by a mutation in the gene ( which is important for the synthesis of iron-sulfur clusters. The primary pathologies of FRDA are loss of motor control and cardiomyopathy.
View Article and Find Full Text PDFUnveiling the Role of TMPRSS2 in the Proteolytic Activation of Pandemic and Zoonotic Influenza Viruses and Coronaviruses in Human Airway Cells.
Viruses
November 2024
Institute of Virology, Philipps-University Marburg, 35043 Marburg, Germany.
Article Synopsis
- The zoonotic transmission of influenza A viruses (IAVs) and coronaviruses (CoVs) can lead to severe diseases, and the cleavage of glycoproteins is essential for their infectivity.
- The study focused on the role of transmembrane serine protease 2 (TMPRSS2) in cleaving viral proteins in human airway cells and its dependency for different IAV and CoV strains.
- Results showed that while TMPRSS2 is crucial for the activation of certain viruses like H1N1/1918 and MERS-CoV, others like SARS-CoV and some IAV subtypes show less dependency, indicating the potential for alternative proteases and highlighting TMPRSS2 as
Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims Analysis.
Adv Ther
November 2024
Sarepta Therapeutics, Inc, Cambridge, MA, 02142, USA.
Article Synopsis
- Phosphorodiamidate morpholino oligomers (PMOs) are weekly intravenous treatments approved for Duchenne muscular dystrophy (DMD) that allow for certain exon skipping, but real-world usage data is scarce.
- The study used data from MarketScan commercial and Medicaid claims between 2018-2021 to analyze PMO treatment patterns, finding 133 patients with claims for PMOs, generally aged around 14 years and predominantly male.
- Results showed a high median proportion of days covered at 83.4%, with over half of the patients maintaining continuous treatment coverage, and a significant majority of those with treatment gaps later resumed PMO claims despite potential underestimations from the claims data.*
Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy.
Drug Metab Dispos
November 2024
Sarepta Therapeutics, Inc., Cambridge, Massachusetts.
Article Synopsis
- Eteplirsen, golodirsen, and casimersen are drugs approved for treating Duchenne muscular dystrophy (DMD) that target specific genetic mutations associated with the disease through a mechanism called exon skipping.
- In studies, these drugs showed similar metabolism and pharmacokinetic properties across various animal models, with consistent plasma exposure and low plasma protein binding.
- The research suggests that these PMOs share key characteristics that could support the development of a broader PMO drug class, potentially leading to new treatments for genetic conditions like DMD.
An Accurate and Fast P qNMR Assay Method for Oligonucleotide Therapeutics.
Anal Chem
October 2024
Division of Pharmaceutical Quality Research II, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Chemically modified nucleic acid molecules have been developed as oligonucleotide therapeutics, and its assay is critical in quality assurance. The common DNA/RNA quantification method using UV-260 nm can lack accuracy because of structure modifications and the possible formation of higher-order structure (HOS). Additionally, process-associated water and counterions affect the accuracy in gravimetric analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!